Regeneron turned down in US on Arcalyst in gout
This article was originally published in Scrip
Executive Summary
Given the overwhelming vote against approval in May by the US FDA’s outside advisers, it came as no surprise on 30 July that regulators rejected Regeneron Pharmaceuticals' supplemental biologics license application for Arcalyst (rilonacept) as a subcutaneous injection to prevent gout flares in patients initiating uric acid-lowering therapy.